<p>Abbreviations: LNs, lymph nodes; G1, well differentiated; G2, moderately differentiated; G3, poorly differentiated; G4, undifferentiated; WBC, white blood cells; NLR, neutrophil—lymphocyte ratio; PLR, platelet—lymphocyte ratio; HR, hazard ratio; CI, confidence interval.</p><p>Patient characteristics of the development and validation set.</p
<p>Characteristics of the patients of 1) the pilot study and 2) the reliability study.</p
Descriptive characteristic of patients in the derivation and validation cohorts.</p
<p>Personal description and treatment of every patient before PET/CT</p><p>Chlorethyl-Cyclohexyl-Nit...
<p>Demographic and Clinicopathological Characteristics of the Development and Validation set.</p
<p>Clinical and pathological characteristics of patients in the validation cohort.</p
<p>SLN, sentinel lymph node; SD, standard deviation.</p><p>Characteristics of patients.</p
<p>Abbreviations: LNs, lymph nodes; G1, well differentiated; G2, moderately differentiated; G3, poor...
<p>Patient characteristics associated with each disease phenotype in the training and test sets.</p
<p>Patient characteristics in the development and external validation samples.</p
<p>Patient characteristics are listed.</p><p>Abbreviations: ECOG PS = Eastern Cooperative Oncology G...
<p>f–female, m–male, B-LCL–B lymphoid cell line, +–positive,—–negative</p><p>Clinical and pathologic...
<p>Patients characteristics in the generation (n = 556) and validation (n = 129) cohorts.</p
<p>Patients’ characteristics of neoplasm samples and control samples used in the discovery and the v...
<p>Characteristics of patients and treatment in the validation sample, consisting of 130,960 IVF cyc...
<p>Clinical characteristics for patients submitted to analyses of plasma and tissue.</p
<p>Characteristics of the patients of 1) the pilot study and 2) the reliability study.</p
Descriptive characteristic of patients in the derivation and validation cohorts.</p
<p>Personal description and treatment of every patient before PET/CT</p><p>Chlorethyl-Cyclohexyl-Nit...
<p>Demographic and Clinicopathological Characteristics of the Development and Validation set.</p
<p>Clinical and pathological characteristics of patients in the validation cohort.</p
<p>SLN, sentinel lymph node; SD, standard deviation.</p><p>Characteristics of patients.</p
<p>Abbreviations: LNs, lymph nodes; G1, well differentiated; G2, moderately differentiated; G3, poor...
<p>Patient characteristics associated with each disease phenotype in the training and test sets.</p
<p>Patient characteristics in the development and external validation samples.</p
<p>Patient characteristics are listed.</p><p>Abbreviations: ECOG PS = Eastern Cooperative Oncology G...
<p>f–female, m–male, B-LCL–B lymphoid cell line, +–positive,—–negative</p><p>Clinical and pathologic...
<p>Patients characteristics in the generation (n = 556) and validation (n = 129) cohorts.</p
<p>Patients’ characteristics of neoplasm samples and control samples used in the discovery and the v...
<p>Characteristics of patients and treatment in the validation sample, consisting of 130,960 IVF cyc...
<p>Clinical characteristics for patients submitted to analyses of plasma and tissue.</p
<p>Characteristics of the patients of 1) the pilot study and 2) the reliability study.</p
Descriptive characteristic of patients in the derivation and validation cohorts.</p
<p>Personal description and treatment of every patient before PET/CT</p><p>Chlorethyl-Cyclohexyl-Nit...